Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modulation of platelet function by diabetes agents in addition to their hypoglycemic effects would contribute to cardiovascular protection Newly introduced antidiabetic drugs of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors may have anti-platelet effects, and in the case of SGLT2i and GLP-1RA may contribute to their proven cardiovascular benefit that has been shown clinically.
|
31612835 |
2020 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
There have been a number of case reports and small clinical series reporting the potential association between dipeptidyl peptidase-4 inhibitors (DPPIs) for diabetes and the onset of bullous pemphigoid (BP).
|
31215644 |
2020 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase-4 inhibitors in treatment-naïve patients with type 2 diabetes in Japan.
|
31145536 |
2020 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase-4 inhibitor (DPP-4-Is), a kind of drug used for the treatment of diabetes, is considered to prevent the degradation of substance P that suppresses the occurrence of dysphagia.
|
31822955 |
2020 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on this evidence, dipeptidyl peptidase-4 inhibitors should be considered for hospitalized patients with type 2 diabetes and an algorithm for this is proposed.
|
31529777 |
2020 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results may have direct translational implications as DPP4 inhibitors are already in clinical use for diabetes.This article is protected by copyright.All rights reserved.
|
31350829 |
2020 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones.
|
31837333 |
2020 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
|
30136384 |
2019 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DPP-4 (dipeptidyl peptidase-4) inhibitors (or "gliptins") represent a class of oral anti-hyperglycemic agents that inhibit the enzyme DPP-4, thus augmenting the biological activity of the "incretin" hormones (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) and restoring many of the pathophysiological problems of diabetes.
|
31366085 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer.
|
29692250 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
DPP4 inhibitors are used to treat diabetes.
|
31124302 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have developed a selective, non-invasive, <sup>13</sup>C-assay for DPP4 that could have broad translational applications in diabetes and gastrointestinal disease.
|
30894647 |
2019 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To characterise the patterns of switching, adherence, and persistence among adults aged ≥18 years with diabetes prescribed dipeptidyl peptidase-4 inhibitors (DPP-4is) in Australia.
|
31697992 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 RAs and DPP-4 inhibitors show promise in the treatment of diabetes and obesity-related subfertility.
|
31260047 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This PS-matched cohort study demonstrated no elevated risk of malignant complications with DPP-4 inhibitor treatment relative to metformin treatment among T2DM patients, irrespective of patient sex, age, comorbid conditions, and diabetes severity status.
|
31496802 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury.
|
30638989 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
While dipeptidyl peptidase-4 (DPP-4) inhibitors exhibited increased heart failure hospitalization in the SAVOR-TIMI 53 trial evaluating saxagliptin and in the secondary analysis of the EXAMINE trial for alogliptin, the effects of glucagon-like peptide-1 (GLP-1) analogs and sodium-glucose co-transporter-2 (SGLT2) inhibitors on CV outcomes in diabetes have largely been positive.
|
30767126 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dipeptidyl peptidase 4 (DPP-4) inhibitors have been shown to have neuroprotective effects in diabetic patients suffering from stroke, but less research has focused on patients with mild hyperglycemia below the threshold for a diagnosis of diabetes.
|
31808042 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Design and Discovery of Novel 1,3,5-Triazines as Dipeptidyl Peptidase-4 Inhibitor against Diabetes.
|
30799431 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
DPP-4 inhibitors are a class of potent anti-glycemic agents used to treat diabetes.
|
31737185 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Terminalia arjuna demonstrated significant DPP-IV Inhibitory, antidiabetic (significant reduction in HbA<sub>1C</sub>) and cardioprotective effects (restoration of myocardial CPK-MB) in the experimental model of myocardial infarction co-existing with diabetes.
|
30668318 |
2019 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the difference in the efficacy among dipeptidyl peptidase-4 (DPP-4) inhibitors in Chinese adults with newly diagnosed diabetes.
|
30822272 |
2019 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Hannaneh and carnosine dipeptides, with preservation of normal β-cell signaling and anti dipeptidyl peptidase-4 activity, prevented blood glucose increases in mice at risk of diabetes.
|
30710452 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study evaluated people with type 2 diabetes taking DPP-4 inhibitor therapy in addition to at least one other diabetes therapy.
|
31264097 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
To describe the cost and utilization outcomes of drugs used to treat diabetes after exclusion of DPP-4 inhibitors in a self-funded managed care plan.
|
31134855 |
2019 |